Freenome company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series E | Alive

Total Raised


Last Raised

$290M | 5 mos ago

About Freenome

Freenome is an AI genomics biotechnology company in South San Francisco, California. By using a blood test, Freenome can help detect and treat cancer quickly and efficiently.

Freenome Headquarter Location

279 East Grand Avenue 5th Fl

South San Francisco, California, 94080,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Freenome

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Freenome is included in 12 Expert Collections, including Digital Health.


Digital Health

13,192 items

Startups recreating how healthcare is delivered


Unicorns- Billion Dollar Startups

1,168 items


AI 100

99 items


Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare


Artificial Intelligence

9,051 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

Freenome Patents

Freenome has filed 6 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • MicroRNA
  • Analytical chemistry
patents chart

Application Date

Grant Date


Related Topics



Bacteriology, Microbiomes, Microbiology, Bacteria, Digestive system


Application Date


Grant Date


Related Topics

Bacteriology, Microbiomes, Microbiology, Bacteria, Digestive system



Latest Freenome News

How to leverage technology to drive diversity in clinical studies

Jun 17, 2022

June 17, 2022 This colorectal cancer screening study enrolled 35,000 patients across the continental U.S. Chuanbo Xu, Freenome Cancer doesn’t discriminate. It’s the second-leading cause of death in the U.S. Early detection is key in treating — and even preventing — cancers like colorectal cancer (CRC). Despite recommendations that everyone over the age of 45 be screened for CRC, nearly a third of people don’t get screened. This lack of screening helps make CRC the second-deadliest cancer in the U.S. For some, taking a few days off work for a colonoscopy is inconvenient. For others, the bowel preparation or stool experience can be uncomfortable or unnerving. To improve adherence and reduce these kinds of barriers, Freenome is developing a test that’s convenient, less cumbersome and easy to administer with a standard blood draw at any doctor’s office or health clinic. With the goal of ensuring our test reaches everyone, it was critical to conduct a broad, representative study that includes everyone. How did we reach patients of a wide variety of ages, races, ethnicities and genders? How did we ensure people in small towns and/or those without insurance or access to health clinics could participate? Convenience was the driver and the traditional clinical trial model had to evolve. We needed to meet patients where they were. And for many, it was online. Going virtual When we designed PREEMPT CRC , our registrational study for a blood-based CRC screening test, it was critical that we make it easy for anyone — in any ZIP code — to participate. This means thinking through all avenues to reach multiple populations. Virtual offerings were key. We created a dedicated website with helpful information and the ability for patients to register right there on the website. With our physician investigators, we offered electronic consenting to make it more convenient for patients to consent online. For those patients who were not comfortable with or close to a hospital or other brick-and-mortar study site, we set up mobile phlebotomy teams to conduct blood draws at patients’ homes. Phone calls and email communication from the study staff provided patients with additional support and information to navigate the study process. And it worked. PREEMPT CRC enrolled more than 35,000 people across patient ages, genders, races, ethnicities and insurance status in both rural and urban areas in every state in the continental U.S. PREEMPT CRC is representative of the real world. Overcoming challenges Like any major operation with a lot of moving parts, we expected challenges. However, we did not anticipate a global pandemic. PREEMPT CRC launched in May 2020 with the goal to offer convenient options for patients and support traditional study sites. As COVID-19 spread across the country, virtual options became even more important. To reach Black and Hispanic patients in addition to underserved communities like those in rural communities or those without access to health clinics, it was important to have communication and support on the ground. Working with partners like the Colorectal Cancer Alliance (CCA), Dia de la Mujer Latina, Intercultural Center for Health Research and Wellness, historically black colleges and universities like Morehouse School of Medicine, and retail pharmacies like CVS Health’s Clinical Trial Services provided patients with the culturally competent materials and education needed to drive enrollment. Plan ahead and think differently for your next clinical trial If you’re planning a clinical study for any therapeutic area, think outside the traditional model and get in the mindset of patients to offer multiple avenues for education, enrollment and participation. Virtual recruitment, electronic consent and mobile phlebotomy create options to reach patients outside of urban areas with teaching hospitals. Community partners extend reach, offer trust and credibility to educate patients on the clinical study process and their role. Finally, enlisting culturally competent staff to help tailor communication to specific populations. Let’s hope diverse clinical studies will become the norm rather than the exception in the coming months. My experience with PREEMPT CRC shows that with some key strategic steps, it’s possible. Chuanbo Xu [Photo courtesy of Freenome] Chuanbo Xu is senior director of clinical development at Freenome. With 20 years of clinical experience, he has led teams across disciplines in developing products that address unmet medical needs. The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of or its employees.

Freenome Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Freenome Rank

  • When was Freenome founded?

    Freenome was founded in 2014.

  • Where is Freenome's headquarters?

    Freenome's headquarters is located at 279 East Grand Avenue, South San Francisco.

  • What is Freenome's latest funding round?

    Freenome's latest funding round is Series E.

  • How much did Freenome raise?

    Freenome raised a total of $1.099B.

  • Who are the investors of Freenome?

    Investors of Freenome include Roche Venture Fund, Andreessen Horowitz, T. Rowe Price, RA Capital Management, Perceptive Advisors and 37 more.

  • Who are Freenome's competitors?

    Competitors of Freenome include Diagu, Owlstone Medical, Inivata, Chronix Biomedical, Thrive Earlier Detection and 11 more.

You May Also Like

20/20 GeneSystems Logo
20/20 GeneSystems

20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.

Owlstone Medical Logo
Owlstone Medical

Owlstone Medical is a diagnostics company developing a breathalyzer for disease detection. Its Breath Biopsy platform enables early detection across multiple cancers and a range of other conditions. Breath Biopsy can also be used to enable precision medicine, ensuring that the right drug is given to the right patient at the right time, helping to improve patient outcomes and reduce healthcare costs.

OncoTAB Logo

OncoTAB's technology was used to develop a blood test, Agkura Personal Score, which aids breast cancer detection in women with dense breast tissue.

Liquid Genomics

Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.


Accuragen has developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in minuscule concentrations of circulating cell-free DNA (cfDNA) in blood. The Company's technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining proprietary techniques in molecular biology and computational algorithm for error suppression. With Accuragen's technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.

Beacon Biomedical Logo
Beacon Biomedical

Beacon Biomedical is a medical diagnostic development and a Centers of Medicare and Medicaid Services (CMS) CLIA accredited laboratory services company providing easy, accurate, and affordable blood tests for earlier cancer detection. Its laboratory-developed test (LDT) solutions are developed for healthcare practitioners and individuals alike and are intended to be used as screening tests for the presence of undiagnosed cancer. They are specifically designed for those who are unwilling or unable to participate in cancer screening using current procedures and tests. The company's focus is on providing blood-based cancer screening alternatives in order to improve screening participation and earlier detection of these devastating diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.